New research about why people forego colorectal cancer screening

NewsGuard 100/100 Score

New research about why people forego colorectal cancer (CRC) screening suggests that three fears play a significant role; fear of embarrassment, fear of getting AIDS and fear of pain may make some seniors skip the potentially lifesaving tests.

The strongest predictor of unwillingness to participate in screening was fear of embarrassment during a screening. Fear of getting AIDS, which prior studies have suggested revolve around the insertion of medical devices into the rectum, was the second strongest. Fear of pain was also associated with a reluctance to participate in screening.

"We found that people who feared that they might get AIDS, feared feeling embarrassed during the screening exam, those who were older, and those with only a high school education were more unwilling to get screened," said lead author Shalanda Bynum, Ph.D., MPH, an assistant professor of social and behavioral sciences at the F. Edward Hebert School of Medicine at the Uniformed Services University of the Health Sciences.

While earlier research has shown that barriers to CRC screening include factors such as income and race/ethnicity, this study, in the American Journal of Health Promotion, sought to explore not only those factors but also psychosocial ones. It is one of the few studies to also address the influence of a person's mistrust of medical providers and misconceptions, such as the notion that CRC screening might cause AIDS.

The AIDS issue warrants further investigation, said Jason Q. Purnell, Ph.D., MPH, an assistant professor at the George Warren Brown School of Social Work at Washington University. It also testifies to the need for public health efforts around CRC screening to increase patients' knowledge and address their fears, said Bynum.

The findings were based on telephone survey data from 454 individuals 50 and older living in New York, Baltimore and San Juan. Study participants self-identified as African American, Hispanic or white. They were asked how willing they were to participate in colon cancer screening and how much various fears or feelings, such as fear of finding out you have cancer or mistrust of doctors, would influence their decision.

One finding that the researchers and Purnell found surprising and consider worthy of closer study was that those who reported medical mistrust were less likely than others to indicate that they would not get screened for CRC.

Purnell said, "Medical mistrust may heighten a person's sense of vigilance, making them more likely to undergo screenings in an attempt to guard against what they perceive as potentially inadequate care. The relationships of mistrust to colorectal cancer screening may be more complex than we originally thought."

People who generally feared developing cancers were also less likely to demonstrate avoidance of screening.

Although colorectal cancer rates have declined greatly in the past 20 years, it remains the second leading cause of cancer death in the US. Despite screening's proven ability to prevent CRC, 38 percent of adults over 50 have never had a sigmoidoscopy/colonoscopy and 79 percent have never had a fecal occult blood test.

Source:

American Journal of Health Promotion

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
UCLA study finds pre-surgery immunotherapy safe for pancreatic cancer patients